The advantages of nilotinib include its high in vitro affinity for BCR–ABL tyrosine kinase, and the improved molecular remission in the treatment of chronic-phase CML with this drug [47, 48]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.